| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |